StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.24+0.03 (+11.89%)

Close on Nov 18, 2026Market cap $568.73KP/E –Yield –

Lakewood-Amedex Biotherapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Lakewood-Amedex Biotherapeutics figures

See a number that looks wrong?